Welcome to our dedicated page for Mangoceuticals news (Ticker: MGRX), a resource for investors and traders seeking the latest updates and insights on Mangoceuticals stock.
Mangoceuticals, Inc. (NASDAQ: MGRX) is a dynamic company focusing on the development, marketing, and sale of men's wellness products and services. Specializing in telemedicine, Mangoceuticals provides a convenient platform for men to access essential healthcare. Through this platform, customers can connect with licensed pharmacies to obtain medications prescribed during telehealth consultations. One of the flagship offerings includes Mango ED products, which have gained significant attention for their effectiveness and ease of access.
In recent achievements, Mangoceuticals has expanded its portfolio to include a wider range of wellness products, continually enhancing user experience and accessibility. The company’s ongoing projects focus on integrating advanced telemedicine technologies to streamline consultation and prescription processes. Financially, Mangoceuticals has shown promising growth, with strategic partnerships bolstering its market presence and operational capabilities.
Mangoceuticals is committed to providing quality healthcare solutions tailored to men's needs, ensuring privacy, convenience, and professional guidance at every stage. Investors and stakeholders can expect steady updates on the company's performance, new product launches, and strategic developments, making MGRX a noteworthy stock in the wellness and telemedicine sectors.
Rhea-AI Summary
Mangoceuticals, Inc. (Nasdaq: MGRX) offers San Francisco players and coaches a free one-year supply of its 'Mango' erectile dysfunction product following a Big Game loss. Fans can also get 3 free Mango pills with a special discount code 'SB58'. The product contains active ingredients from Cialis and Viagra, compounded with Oxytocin and L-Arginine in a Mango-flavored rapid dissolve tablet.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.36%
Tags
-
Rhea-AI Summary
Mangoceuticals, Inc. (Nasdaq: MGRX) announces a promotion offering the losing team of the Big Game a free one-year supply of its Mango ED products. Fans can also get a special discount code equal to the game's point difference. The company's uniquely formulated Mango ED products are designed to help men tackle performance issues in the bedroom. MangoRx will also be the marquee sponsor for several Barstool Sports' week-long programming surrounding the Big Game in Las Vegas.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.59%
Tags
-
Rhea-AI Summary
Mangoceuticals, Inc. (NASDAQ: MGRX) is offering 2 months of free ‘PRIME’ by MangoRx, Powered by Kyzatrex®️ for the first 1,000 male subscribers interested in subscribing to the oral testosterone replacement protocol. The company is also providing discounted prices for a minimally invasive FDA approved at-home blood collection test kit through their nationwide lab partnership with Trybe Labs. Jacob Cohen, MangoRx’s Co-Founder and CEO, expressed excitement about the official PRIME launch and the one-time promotion for the first 1,000 interested subscribers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.03%
Tags
Rhea-AI Summary
Mangoceuticals, Inc. (Nasdaq: MGRX) announces its sponsorship of Barstool Sports' week-long programming schedule surrounding the Big Game in Las Vegas, featuring its FDA-approved oral Testosterone Replacement 'Prime' by MangoRx, powered by Kyzatrex. The company will be a Marquee Sponsor and will be featured across Barstool programming during the week of the Super Bowl, reaching an estimated number of over 7 million views and impressions. The partnership aims to showcase 'Prime' to the passionate fans of Barstool Sports and expand broad-based consumer access to this revolutionary therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.83%
Tags
-
Rhea-AI Summary
Mangoceuticals, Inc. (Nasdaq: MGRX) announced the pricing of its underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $0.30 per share, with aggregate gross proceeds of $1,200,000 to the Company. The Company has also granted the underwriters a 45-day option to purchase up to an additional 600,000 shares of its common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-40.96%
Tags
-
Rhea-AI Summary
Mangoceuticals, Inc. (NASDAQ: MGRX) announces a marketing agreement with Marius Pharmaceuticals to launch KYZATREX, an FDA-approved oral Testosterone Replacement Therapy, under the program PRIME by MangoRx. KYZATREX is expected to be available on MangoRx's telemedicine platform starting January 31, 2024. The new therapy aims to address testosterone deficiency in men, with a focus on providing a convenient and effective treatment option.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
Rhea-AI Summary
Mangoceuticals, Inc. (NASDAQ: MGRX) is expanding its sales access across Latin America with the establishment of its subsidiary, MangoRx Mexico, aiming to tap into the Mexican market for men's health and wellness products, particularly its uniquely formulated hair growth product 'GROW' and erectile dysfunction (ED) drug 'Mango'. The company has engaged Diaz Reus International Law Firm for establishing its subsidiary presence in Mexico and is in the process of establishing manufacturing and distribution partnerships. The estimated annual market size in Mexico for ED pharmaceutical products is USD $216 million with approximately 24 million units sold annually and growing at a rate of 4% per year at an average sales price of USD $8.50 per unit.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
-
News
Rhea-AI Summary
Mangoceuticals, Inc. (NASDAQ: MGRX) announces partnership with TRYBE Labs to provide at-home blood collection services for its men's health and wellness products. The collaboration aims to expand product lines requiring blood tests and results reviewed by physicians, offering innovative, convenient, and minimally invasive solutions for male health and performance evaluation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.61%
Tags
-
Rhea-AI Summary
Mangoceuticals, Inc. (NASDAQ:MGRX) announces the addition of 'Grow,' a hair growth treatment, to its men's health product line. Combining Minoxidil, Finasteride, Vitamin D3, and Biotin in chewable tablets, the product is available for delivery by prescription through MangoRx's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
Rhea-AI Summary
Mangoceuticals, Inc. (NASDAQ: MGRX) announces that it will donate 50% of proceeds from the sale of its branded merchandise to men's health and wellness charities throughout November. The donations will support education and awareness around prostate cancer, testicular cancer, and men's suicide. Prostate cancer is the second most diagnosed cancer in the US.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.77%
Tags
FAQ
What is the current stock price of Mangoceuticals (MGRX)?
The current stock price of Mangoceuticals (MGRX) is $2.52 as of December 24, 2024.
What is the market cap of Mangoceuticals (MGRX)?
The market cap of Mangoceuticals (MGRX) is approximately 6.3M.
What is Mangoceuticals, Inc.?
Mangoceuticals, Inc. is a company specializing in men's wellness products and services, primarily through a telemedicine platform.
What products does Mangoceuticals offer?
Mangoceuticals offers a range of men's wellness products, including Mango ED products, which are accessible via their telemedicine platform.
How does Mangoceuticals' telemedicine platform work?
The platform allows customers to consult with healthcare professionals online, who can then prescribe medications that are fulfilled and distributed by licensed pharmacies.
What recent achievements has Mangoceuticals made?
Mangoceuticals has expanded its product range and integrated advanced technologies to improve telehealth consultations and prescription processes.
What is the financial condition of Mangoceuticals?
Mangoceuticals has shown promising growth, supported by strategic partnerships that enhance its market presence and operational capabilities.
Who can benefit from Mangoceuticals' services?
Men looking for convenient and private access to wellness products and telehealth consultations can benefit from Mangoceuticals' services.
What is the significance of Mango ED products?
Mango ED products are notable for their effectiveness in treating erectile dysfunction, with the added convenience of being accessible online.
What makes Mangoceuticals noteworthy in the stock market?
Mangoceuticals is noteworthy for its innovative approach to men's wellness, strong growth potential, and commitment to expanding its product and service offerings.
How does Mangoceuticals ensure the privacy of its customers?
Mangoceuticals ensures privacy through secure telehealth consultations and discrete prescription fulfillment processes.
What should investors expect from Mangoceuticals in the future?
Investors can expect ongoing updates on performance, new product innovations, and strategic developments that may impact the company's market position.
Mangoceuticals, Inc.
Nasdaq:MGRX
MGRX Rankings
MGRX Stock Data
6.27M
1.74M
37.45%
4.69%
7.69%
Health Information Services
Services-misc Health & Allied Services, Nec
United States of America
DALLAS